Moleculin to present new Annamycin data at AACR pancreatic cancer conference and two European scientific meetings

Moleculin Biotech, Inc.

Three September 2026 presentations examine Annamycin tissue distribution, topoisomerase II inhibition, and CD8+ T cell-mediated antitumor activity.
Presentations include Sept 25-28 AACR Pancreatic Cancer Conference in San Diego, plus Polish meetings on Sept 9-12 and Sept 14.
Waldemar Priebe (MD Anderson) presents two talks; Angela Alistar (Atlantic Health) presents AACR abstract on pancreatic cancer.
MIRACLE trial in relapsed/refractory AML remains the primary development focus and basis of near-term milestones.
AACR abstract under embargo until publication on Sept 25, 2026 at 1:00 p.m. ET.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.